Tips for Pharmaceutical Research & Drug Development

Identifying the signs that a prototype is not scalable is the first step in mitigating the problem. Here are key symptoms that may indicate issues with scalability:Click to read the…

Identifying potential bioavailability risks during early development begins with recognizing key symptoms and signals. These may manifest on the production floor or in laboratory settings:Click to read the full article.

Symptoms of excipient incompatibility can manifest in various ways during the manufacturing process. These can include:Click to read the full article.

Identifying symptoms of excipient incompatibility requires astute observation and data analysis. Symptoms may vary but can typically include:Click to read the full article.

Identifying stability failures early is crucial in preventing further complications in the formulation development process. Symptoms may manifest as:Click to read the full article.

Identifying symptoms indicative of bioavailability risks can prevent costly setbacks. Common signals observed during manufacturing, formulation development, or laboratory testing include:Click to read the full article.

Failure to adequately incorporate QbD principles during tech transfer can surface as various signals either on the production floor or within the lab. Common symptoms to watch for include:Click to…

Addressing Late-Identified Excipient Incompatibilities During Regulatory Reviews In the dynamic landscape of pharmaceutical formulation development, identifying excipient incompatibilities late in the regulatory review process can pose significant risks to product…

Understanding the symptoms of potential bioavailability issues is critical. Key signals include:Click to read the full article.

During the formulation and development phases, certain symptoms may indicate underlying bioavailability risks. Identifying these signals early is critical to minimizing delays and ensuring compliance.Click to read the full article.

Dissolution variability symptoms may surface as early as initial formulation testing and can become pronounced during scale-up activities. Common indicators include:Click to read the full article.

Identifying the symptoms or signals of a non-scalable prototype is the first step in addressing the issue. Common indicators may include:Click to read the full article.